All Updates

All Updates

icon
Filter
Partnerships
HuidaGene and Synthego enter licensing agreement to advance CRISPR-based genomic medicines
Human Gene Editing
May 29, 2024
This week:
Funding
Lhyfe receives EUR 11 million grant from Klimatklivet for green hydrogen project in Sweden
Hydrogen Economy
Yesterday
Product updates
XRAI Glass launches AR One glasses at USD 1449 for hearing-impaired individuals
Extended Reality
Yesterday
Funding
VR therapy platform CUREosity raises EUR 3.8 million in funding to expand market presence
Extended Reality
Yesterday
Last week:
Product updates
Coinbase updates mobile wallet to add decentralized app browser
Decentralized Finance (DeFi)
Jun 22, 2024
Product updates
Coinbase updates mobile wallet to add decentralized app browser
Web3 Ecosystem
Jun 22, 2024
M&A
OpenAI acquires Rockset to power retrieval infrastructure
Data Infrastructure & Analytics
Jun 21, 2024
M&A
OpenAI acquires Rockset to power retrieval infrastructure
Foundation Models
Jun 21, 2024
Partnerships
Product updates
Anthropic releases Claude 3.5 Sonnet, the first model in the 3.5 series
Foundation Models
Jun 21, 2024
Funding
Paramount Planet Product raises USD 1 million in federal grant funding to support commercialization
Bio-based Materials
Jun 21, 2024
Regulation/policy
Apple delays launch of Apple Intelligence features in EU citing regulatory concerns
Generative AI Applications
Jun 21, 2024
Human Gene Editing

Human Gene Editing

May 29, 2024

HuidaGene and Synthego enter licensing agreement to advance CRISPR-based genomic medicines

Partnerships

  • Gene-editing companies Synthego and HuidaGene Therapeutics have entered a collaboration to license HuidaGene's high-fidelity Cas12 CRISPR nuclease (hfCas12Max). The terms and financial details of the agreement have not been disclosed.

  • As per the agreement, HuidaGene will grant Synthego the rights to manufacture and commercialize the hfCas12Max nuclease and sublicense it for therapeutic use.

  • The collaboration aims to streamline the development of CRISPR-based therapeutic applications, providing developers access to efficient genome-editing tools.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.